Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes

Molecular Cancer Research

Volumn 13, Issue 2, 2015, Pages 250-262

  Kung, Che Pei ^a   Khaku, Sakina ^a   Jennis, Matthew ^a,b   Zhou, Yan ^c   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; CARRIER PROTEIN; TP53 PROTEIN, HUMAN; TRIML2 PROTEIN, HUMAN; TRIML2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FIBROBLAST; GENE EXPRESSION; GENE TRIML2; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN MODIFICATION; SUMOYLATION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; ANIMAL; CELL CULTURE; CYTOLOGY; DNA MICROARRAY; GENE TARGETING; GENETICS; HCT 116 CELL LINE; METABOLISM; MOLECULAR GENETICS; MUTATION;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELLS, CULTURED; FIBROBLASTS; GENE KNOCK-IN TECHNIQUES; HCT116 CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SUMOYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923861307     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0385     Document Type: Article

References (48)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-58.
2. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
3. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
4. Carvajal LA, Manfredi JJ. Another fork in the road-life or death decisions by the tumour suppressor p53. EMBO Rep 2013;14:414-21.
5. Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 2011;223:127-36.
6. Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ 2006;13:916-20.
7. Beckman G, Birgander R, Sjalander A, SahaN, Holmberg PA, Kivela A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
8. Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 2009;84:534-41.
9. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
10. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
11. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
12. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, et al. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.Mol Cell Biol 2011;31:1201-13.
13. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
14. Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2011;30:1108-16.
15. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
16. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010-4.
17. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-42.
18. Azzam GA, Frank AK, Hollstein M, Murphy ME. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 2011;10:1352-5.
19. Salvioli S, Bonafe M, Barbi C, Storci G, Trapassi C, Tocco F, et al. p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 2005;4:1264-71.
20. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011;145:571-83.
21. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004;304:843-6.
22. Park JG, Kramer BS, Steinberg SM,Carmichael J, Collins JM, Minna JD, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987;47:5875-9.
23. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011;11:792-804.
24. Stindt MH, Carter S, Vigneron AM, Ryan KM, Vousden KH. MDM2 promotes SUMO-2/3 modifi cation of p53 to modulate transcriptional activity. Cell Cycle 2011;10:3176-88.
25. Li T, Santockyte R, Shen RF, Tekle E,Wang G, Yang DC, et al. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J Biol Chem 2006;281:36221-7.
26. Fukuda I, Ito A, HiraiG, Nishimura S, KawasakiH, SaitohH, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol 2009;16:133-40.
27. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 2001;276:35368-74.
28. Tammsalu T, Matic I, Jaffray EG, Ibrahim AF, Tatham MH, Hay RT. Proteome-wide identification of SUMO2 modification sites. Sci Signal 2014;7:rs2.
29. Azzam G, Wang X, Bell D, Murphy ME. CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest. PLoS ONE 2013;8: e74297.
30. Weige CC, Birtwistle MR, Mallick H, Yi N, Berrong Z, Cloessner E, et al. Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Mol Cancer Res 2014;12:1029-41.
31. Ozato K, Shin DM,Chang TH, MorseHCIII. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008;8:849-60.
32. Ouyang J, Shi Y, Valin A, Xuan Y, Gill G. Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex. Mol Cell 2009;34:145-54.
33. Jain AK, Allton K, Duncan AD, Barton MC. TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated phosphorylation and autodegradation during DNA damage. Mol Cell Biol 2014;34:2695-709.
34. Caratozzolo MF,Micale L, Turturo MG, Cornacchia S, Fusco C,Marzano F, et al. TRIM8 modulates p53 activity to dictate cell-cycle arrest. Cell Cycle 2012;11:511-23.
35. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, et al. PML is a direct p53 target that modulates p53 effector functions.Mol Cell 2004;13:523-35.
36. Obad S, Brunnstrom H, Vallon-Christersson J, Borg A,Drott K, Gullberg U. Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 2004;23:4050-9.
37. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004;6:665-72.
38. Joo HM, Kim JY, Jeong JB, Seong KM, Nam SY, Yang KH, et al. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2. Eur J Cell Biol 2011;90:420-31.
39. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A 2009;106:11612-6.
40. Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ III, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J 2005;24:3279-90.
41. Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, et al. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol 2010;30:3004-15.
42. Zhang L, Huang NJ, Chen C, Tang W, Kornbluth S. Ubiquitylation of p53 by the APC/C inhibitor Trim39. Proc Natl Acad Sci U S A 2012;109:20931-6.
43. Reddy BA, van der Knaap JA, Bot AG, Mohd-Sarip A, Dekkers DH, Timmermans MA, et al. Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization. Mol Cell 2014;53:458-70.
44. Wu SY, Chiang CM. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J 2009;28:1246-59.
45. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007;121:1481-6.
46. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-9.
47. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-90.
48. Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among noncarriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 2005;229:77-83.